Shandong Oriental Ocean reports H1 loss, medical device approval

Shandong Oriental Ocean Sci-Tech Co., Ltd. reported its 2025 semi-annual results, with revenue of CNY 156,041,607.30 and a net loss attributable to shareholders of CNY 71,014,445.28. The company's total assets stood at CNY 1,682,661,258.89, with net assets attributable to shareholders at CNY 1,360,476,062.90. No cash dividends, bonus shares, or capital increases from the provident fund are planned.

In a significant development for its healthcare division, wholly-owned subsidiary Evico Biotechnology Co., Ltd. secured a medical device registration certificate for its Serum Amyloid A (SAA) Quantitative Reagent Kit (Fluorescence Immunochromatography) on August 25, 2025. This approval expands Evico Biotechnology's clinical testing product line, though its impact on the company's 2025 performance is expected to be minor. The company's main business includes marine aquaculture, aquatic product processing, biotechnology, bonded warehousing and logistics, and research, development, production, and sales of in-vitro diagnostic reagents.